SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $18,546.40 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 3,824 shares of SOPHiA GENETICS stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $4.85, for a total value of $18,546.40. Following the completion of the sale, the insider owned 215,451 shares of the company’s stock, valued at approximately $1,044,937.35. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Tuesday, April 7th, Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,571.12.
• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $1,820.20.

SOPHiA GENETICS Price Performance

Shares of SOPH stock opened at $4.70 on Monday. The stock has a 50-day moving average price of $4.75 and a 200 day moving average price of $4.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a market cap of $321.90 million, a price-to-earnings ratio of -9.22 and a beta of 1.04. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Guggenheim raised their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter valued at approximately $6,708,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. Renaissance Technologies LLC increased its position in shares of SOPHiA GENETICS by 169.5% during the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after purchasing an additional 52,200 shares during the last quarter. Akre Capital Management LLC increased its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.